{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T09:37:20Z","timestamp":1782293840262,"version":"3.54.5"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"Horizon 2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["765394"],"award-info":[{"award-number":["765394"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C18915\/A29362"],"award-info":[{"award-number":["C18915\/A29362"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","award":["PID2020-112892RB-100"],"award-info":[{"award-number":["PID2020-112892RB-100"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","award":["PID2020-113174-RA-100 MCIN\/AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["PID2020-113174-RA-100 MCIN\/AEI\/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017266","name":"Gobierno de Navarra","doi-asserted-by":"publisher","award":["0011\u20131411-2023"],"award-info":[{"award-number":["0011\u20131411-2023"]}],"id":[{"id":"10.13039\/501100017266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007406","name":"Fundaci\u00f3n BBVA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007406","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","award":["PI22\/00147"],"award-info":[{"award-number":["PI22\/00147"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["SAF2014-52361-R"],"award-info":[{"award-number":["SAF2014-52361-R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["AC16\/00015"],"award-info":[{"award-number":["AC16\/00015"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.omtn.2023.07.026","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T21:16:17Z","timestamp":1690492577000},"page":"668-682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-\u03b2 antagonists"],"prefix":"10.1016","volume":"33","author":[{"given":"Assunta","family":"Cirella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elixabet","family":"Bola\u00f1os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Luri-Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Augusta","family":"Di Trani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Olivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Gomis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Glez-Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Pinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saray","family":"Garasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"S\u00e1nchez-Gregorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantza","family":"Azpilikueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1aki","family":"Eguren-Santamaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karmele","family":"Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Palencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Teijeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Berraondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-348X","authenticated-orcid":false,"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2023.07.026_bib1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.coi.2014.01.002","article-title":"Orchestrating immune check-point blockade for cancer immunotherapy in combinations","volume":"27","author":"Perez-Gracia","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.omtn.2023.07.026_bib2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omtn.2023.07.026_bib3","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1093\/annonc\/mdy423","article-title":"Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)","volume":"29","author":"Marabelle","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omtn.2023.07.026_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4049\/jimmunol.1601145","article-title":"Intratumoral Delivery of Immunotherapy-Act Locally, Think Globally","volume":"198","author":"Aznar","year":"2017","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtn.2023.07.026_bib5","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/2326-6066.CIR-22-0373","article-title":"Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity","volume":"11","author":"Cirella","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omtn.2023.07.026_bib6","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd.2018.132","article-title":"An RNA toolbox for cancer immunotherapy","volume":"17","author":"Pastor","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2023.07.026_bib7","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1158\/1078-0432.CCR-21-3304","article-title":"RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System","volume":"28","author":"De Mey","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2023.07.026_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc7804","article-title":"Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models","volume":"13","author":"Hotz","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2023.07.026_bib9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2326-6066.CIR-15-0163","article-title":"Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells","volume":"4","author":"Van Lint","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omtn.2023.07.026_bib10","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1038\/s41591-022-02061-1","article-title":"The landscape of mRNA nanomedicine","volume":"28","author":"Huang","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2023.07.026_bib11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ymthe.2005.02.011","article-title":"Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas","volume":"12","author":"Rodriguez-Madoz","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.07.026_bib12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omtn.2023.07.026_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108189","article-title":"Novel strategies exploiting interleukin-12 in cancer immunotherapy","volume":"239","author":"Cirella","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.omtn.2023.07.026_bib14","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2023.07.026_bib15","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2023.07.026_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nbt0197-35","article-title":"Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in\u00a0vivo","volume":"15","author":"Lieschke","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2023.07.026_bib17","doi-asserted-by":"crossref","first-page":"11302","DOI":"10.1073\/pnas.93.21.11302","article-title":"Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma","volume":"93","author":"Caruso","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2023.07.026_bib18","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1158\/1078-0432.CCR-20-0472","article-title":"Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment","volume":"26","author":"Hewitt","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2023.07.026_bib19","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.annonc.2019.12.008","article-title":"Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients","volume":"31","author":"Algazi","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omtn.2023.07.026_bib20","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1158\/2326-6066.CIR-19-0359","article-title":"Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses","volume":"8","author":"Greaney","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omtn.2023.07.026_bib21","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.annonc.2021.01.033","article-title":"19O Preliminary safety, antitumor activity and pharmacodynamics results of HIT-IT MEDI1191 (mRNA IL-12) in patients with advanced solid tumours and superficial lesions","volume":"32","author":"Hamid","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omtn.2023.07.026_bib22","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.4049\/jimmunol.168.3.1146","article-title":"Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1","volume":"168","author":"Nakahira","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtn.2023.07.026_bib23","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/382174a0","article-title":"Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice","volume":"382","author":"Kaplan","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2023.07.026_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.575597","article-title":"Localized Interleukin-12 for Cancer Immunotherapy","volume":"11","author":"Nguyen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2023.07.026_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat9143","article-title":"Durable anticancer immunity from intratumoral administration of IL-23, IL-36\u03b3, and OX40L mRNAs","volume":"11","author":"Hewitt","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2023.07.026_bib26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/bs.ircmb.2022.05.002","article-title":"Overcoming the limitations of cytokines to improve cancer therapy","volume":"369","author":"Di Trani","year":"2022","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.omtn.2023.07.026_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax4738","article-title":"Twists and turns to translating 4-1BB cancer immunotherapy","volume":"11","author":"Sanmamed","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2023.07.026_bib28","article-title":"New emerging targets in cancer immunotherapy: CD137\/4-1BB costimulatory axis","volume":"4","author":"Etxeberria","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.omtn.2023.07.026_bib29","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm0697-682","article-title":"Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors","volume":"3","author":"Melero","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2023.07.026_bib30","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-21-1345","article-title":"Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors","volume":"12","author":"Muik","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omtn.2023.07.026_bib31","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1158\/2159-8290.CD-22-0219","article-title":"Converting Tumoral PD-L1 into a 4-1BB Agonist for Safer and More Effective Cancer Immunotherapy","volume":"12","author":"Li","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omtn.2023.07.026_bib32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.immunol.25.022106.141609","article-title":"Immunosuppressive Strategies that are Mediated by Tumor Cells","volume":"25","author":"Rabinovich","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.omtn.2023.07.026_bib33","first-page":"1155","article-title":"Transforming Growth Factor \u03b2 and Cyclosporin A Inhibit the Inducible Activity\u00a0of the Interleukin-2 Gene in T Cells Through a Noncanonical Octamer-Binding Site","volume":"13","author":"Brabletz","year":"1993","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2023.07.026_bib34","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1073\/pnas.0408197102","article-title":"Regulatory T\u00a0cells suppress tumor-specific CD8 T\u00a0cell cytotoxicity through TGF-beta signals in\u00a0vivo","volume":"102","author":"Chen","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2023.07.026_bib35","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming Growth Factor-\u03b2 Signaling in Immunity and Cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2023.07.026_bib36","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1074-7613(00)80170-3","article-title":"Abrogation of TGFbeta signaling in T\u00a0cells leads to spontaneous T\u00a0cell differentiation and autoimmune disease","volume":"12","author":"Gorelik","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2023.07.026_bib37","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/nm1001-1118","article-title":"Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T\u00a0cells","volume":"7","author":"Gorelik","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2023.07.026_bib38","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/nrd1580","article-title":"Development of TGF-\u03b2 signalling inhibitors for cancer therapy","volume":"3","author":"Yingling","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2023.07.026_bib39","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.4049\/jimmunol.142.5.1536","article-title":"Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification","volume":"142","author":"Dasch","year":"1989","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtn.2023.07.026_bib40","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1158\/1535-7163.MCT-18-0558","article-title":"TGF\u03b2 Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies","volume":"18","author":"Rodr\u00edguez-Ruiz","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.omtn.2023.07.026_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090353","article-title":"Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGF\u03b2) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma","volume":"9","author":"Morris","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2023.07.026_bib42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-021-01053-x","article-title":"Novel therapies emerging in oncology to target the TGF-\u03b2 pathway","volume":"14","author":"Kim","year":"2021","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.omtn.2023.07.026_bib43","first-page":"4479","article-title":"Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway","volume":"9","author":"Herbertz","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.omtn.2023.07.026_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan5488","article-title":"Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-\u03b2","volume":"10","author":"Lan","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2023.07.026_bib45","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1158\/1078-0432.CCR-17-2653","article-title":"Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF\u03b2, in Advanced Solid Tumors","volume":"24","author":"Strauss","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2023.07.026_bib46","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1158\/1078-0432.CCR-13-2116","article-title":"Intratumoral immunization: a new paradigm for cancer therapy","volume":"20","author":"Marabelle","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2023.07.026_bib47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1084\/jem.186.1.47","article-title":"4-1BB costimulatory signals preferentially induce CD8+ T\u00a0cell proliferation and lead to the amplification in\u00a0vivo of cytotoxic T\u00a0cell responses","volume":"186","author":"Shuford","year":"1997","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omtn.2023.07.026_bib48","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nm.4356","article-title":"Elimination of large tumors in mice by mRNA-encoded bispecific antibodies","volume":"23","author":"Stadler","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2023.07.026_bib49","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1006\/abio.1994.1042","article-title":"An Assay for Transforming Growth Factor-\u03b2 Using Cells Transfected with a Plasminogen Activator Inhibitor-1 Promoter-Luciferase Construct","volume":"216","author":"Abe","year":"1994","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.omtn.2023.07.026_bib50","article-title":"Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy","volume":"9","author":"Alvarez","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omtn.2023.07.026_bib51","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1158\/2326-6066.CIR-14-0216","article-title":"Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes with PD-1\/PD-L1 Blockade","volume":"3","author":"Quetglas","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omtn.2023.07.026_bib52","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1471-4906(00)01824-X","article-title":"IL-12 gene therapy for cancer: in synergy with other immunotherapies","volume":"22","author":"Melero","year":"2001","journal-title":"Trends Immunol."},{"key":"10.1016\/j.omtn.2023.07.026_bib53","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/CJI.0b013e318031a2b2","article-title":"Enhancing antitumor immunity: combining IL-12 with TGFbeta1 antagonism","volume":"30","author":"Fan","year":"2007","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omtn.2023.07.026_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101322","article-title":"NHS-IL12 and bintrafusp alfa combination therapy enhances antitumor activity in preclinical cancer models","volume":"16","author":"Xu","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.omtn.2023.07.026_bib55","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41467-018-08123-8","article-title":"CD73 expression on effector T\u00a0cells sustained by TGF-\u03b2 facilitates tumor resistance to anti-4-1BB\/CD137 therapy","volume":"10","author":"Chen","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2023.07.026_bib56","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1006\/mthe.2000.0086","article-title":"Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation","volume":"2","author":"Chen","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.07.026_bib57","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/mt.2012.56","article-title":"Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12","volume":"20","author":"Quetglas","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.07.026_bib58","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/17460441.2021.1978972","article-title":"Advances in mRNA-based drug discovery in cancer immunotherapy","volume":"17","author":"Di Trani","year":"2022","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.omtn.2023.07.026_bib59","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/mt.2011.37","article-title":"Development of a liver-specific Tet-on inducible system for AAV vectors and its application in the treatment of liver cancer","volume":"19","author":"Vanrell","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.07.026_bib60","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1038\/s41467-018-07195-w","article-title":"A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity","volume":"9","author":"Compte","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2023.07.026_bib61","doi-asserted-by":"crossref","first-page":"10100","DOI":"10.18632\/oncotarget.2463","article-title":"Intratumoral administration of mRNA encoding a fusokine consisting of IFN-\u03b2 and the ectodomain of the TGF-\u03b2 receptor II potentiates antitumor immunity","volume":"5","author":"Van der Jeught","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.omtn.2023.07.026_bib62","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1073\/pnas.0611646104","article-title":"Dendritic cells with TGF-beta1 differentiate naive CD4+CD25- T\u00a0cells into islet-protective Foxp3+ regulatory T\u00a0cells","volume":"104","author":"Luo","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2023.07.026_bib63","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.4049\/jimmunol.181.8.5194","article-title":"Cutting edge: Autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells","volume":"181","author":"Belladonna","year":"2008","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtn.2023.07.026_bib64","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1084\/jem.20030152","article-title":"Conversion of peripheral CD4+CD25- naive T\u00a0cells to CD4+CD25+ regulatory T\u00a0cells by TGF-beta induction of transcription factor Foxp3","volume":"198","author":"Chen","year":"2003","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omtn.2023.07.026_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aak9702","article-title":"Blockade of surface-bound TGF-\u03b2 on regulatory T\u00a0cells abrogates suppression of effector T\u00a0cell function in the tumor microenvironment","volume":"10","author":"Budhu","year":"2017","journal-title":"Sci. Signal."},{"key":"10.1016\/j.omtn.2023.07.026_bib66","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1084\/jem.20080308","article-title":"CD4+ FoxP3+ regulatory T\u00a0cells confer infectious tolerance in a TGF-beta-dependent manner","volume":"205","author":"Andersson","year":"2008","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omtn.2023.07.026_bib67","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1158\/2326-6066.CIR-21-0030","article-title":"CD137 Costimulation Counteracts TGF\u03b2 Inhibition of NK-cell Antitumor Function","volume":"9","author":"Cabo","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omtn.2023.07.026_bib68","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s00262-021-03081-5","article-title":"TGF-\u03b2 orchestrates the phenotype and function of monocytic myeloid-derived suppressor cells in colorectal cancer","volume":"71","author":"Gneo","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omtn.2023.07.026_bib69","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00262-011-1119-y","article-title":"The small molecule TGF-\u03b2 signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis","volume":"61","author":"Garrison","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omtn.2023.07.026_bib70","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The Next Decade of Immune Checkpoint Therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omtn.2023.07.026_bib71","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1073\/pnas.85.16.5884","article-title":"Interferon-induced transcription of a major histocompatibility class I gene accompanies binding of inducible nuclear factors to the interferon consensus sequence","volume":"85","author":"Shirayoshi","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2023.07.026_bib72","first-page":"84","article-title":"Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma","volume":"9","author":"Propper","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2023.07.026_bib73","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2326-6066.CIR-18-0940","article-title":"Systemic Interferon-\u03b3 Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial","volume":"7","author":"Zhang","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omtn.2023.07.026_bib74","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ejca.2021.08.004","article-title":"Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition","volume":"157","author":"Yuan","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.omtn.2023.07.026_bib75","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2159-8290.CD-22-1029","article-title":"CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary","volume":"13","author":"Melero","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omtn.2023.07.026_bib76","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abp9229","article-title":"A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors","volume":"15","author":"Melero","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2023.07.026_bib77","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/1078-0432.CCR-20-1830","article-title":"OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and\/or Ipilimumab in Patients With Advanced Solid Tumors","volume":"27","author":"Gutierrez","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2023.07.026_bib78","article-title":"First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)","volume":"11","author":"Postel-Vinay","year":"2023","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omtn.2023.07.026_bib79","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1158\/1078-0432.CCR-21-4020","article-title":"First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors","volume":"28","author":"Kim","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2023.07.026_bib80","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1126\/science.abk3436","article-title":"Oncolytic virotherapy as immunotherapy","volume":"374","author":"Melcher","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.omtn.2023.07.026_bib81","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1056\/NEJMcibr2009737","article-title":"Amplifying RNA Vaccine Development","volume":"382","author":"Fuller","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2023.07.026_bib82","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.omtn.2022.07.020","article-title":"Intratumoral electroporation of a self-amplifying RNA expressing IL-12 induces antitumor effects in mouse models of cancer","volume":"29","author":"Silva-Pilipich","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2023.07.026_bib83","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1158\/1078-0432.CCR-20-3250","article-title":"Interleukin-12 Message in a Bottle","volume":"26","author":"Cirella","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2023.07.026_bib84","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/2159-8290.CD-15-0510","article-title":"Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti\u2013PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells","volume":"6","author":"S\u00e1nchez-Paulete","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omtn.2023.07.026_bib85","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ccell.2019.10.006","article-title":"Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells","volume":"36","author":"Etxeberria","year":"2019","journal-title":"Cancer Cell"}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253123001993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253123001993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:42:18Z","timestamp":1761874938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253123001993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":85,"alternative-id":["S2162253123001993"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2023.07.026","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-\u03b2 antagonists","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2023.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}]}}